Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: J Immunol. 2009 May 1;182(9):5537–5546. doi: 10.4049/jimmunol.0803742

FIGURE 3.

FIGURE 3

Anti-angiogenesis vaccines are not effective in mice tolerant to HER-2/neu. A, FVB/N wild-type (WT) or FVB/N transgenic (Tg) mice were injected with 1 × 106 NT-2 cells s.c.; tumors were allowed to grow until palpable before treatment started. Mice were immunized a total of three times; mean tumor sizes are shown here for up to 69 days posttumor inoculation. Graphs show mean ± SEM; *, p < 0.05; Mann-Whitney U test, experiment repeated twice. B, Spleens were processed for IFN-γ ELISPOTs, and stimulated with various Her-2/neu peptides ex vivo, or a third-party peptide as a negative control (pGag). Graphs show mean ± SEM; *, p < 0.05; Mann-Whitney U test, experiment repeated once. C, Tumors from each group were pooled and digested for TILs; here we show Her-2/neu-specific T cells staining for CD8α and EC1- or IC1-specific tetramers. Significantly more Her-2/neu-specific T cells are found in the wild-type (WT), but not transgenic (Tg) mice; control Lm group shows low background. Experiment repeated once, giving similar results.